Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsToni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffen WALTER, Harpreet SINGH
Estimating the term…
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
A pharmaceutical composition comprising a peptide consisting of the amino acid sequence selected from SEQ ID NOs:
An in vitro method for producing activated antigen-specific CD8+ cytotoxic T lymphocytes, comprising contacting in vitro T cells with antigen loaded human HLA-A*02 expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide consisting of the amino acid sequence selected from SEQ ID NOs:
Dependencies are inferred from the claim text.